Opko Health CEO Phillip Md Et Al Frost Acquires 35,000 Shares (OPK)
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 35,000 shares of the stock on the open market in a transaction that occurred on Wednesday, August 27th. The shares were purchased at an average price of $8.88 per share, with a total value of $310,800.00. Following the completion of the transaction, the chief executive officer now directly owns 2,012,377 shares in the company, valued at approximately $17,869,908. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Opko Health (NYSE:OPK) traded down 0.79% on Thursday, hitting $8.82. The stock had a trading volume of 677,806 shares. Opko Health has a 1-year low of $7.32 and a 1-year high of $12.95. The stock has a 50-day moving average of $8.9 and a 200-day moving average of $8.87. The company’s market cap is $3.785 billion.
Opko Health (NYSE:OPK) last announced its earnings results on Monday, August 11th. The company reported ($0.06) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter last year, the company posted ($0.01) earnings per share. Opko Health’s revenue was down 1.3% compared to the same quarter last year. On average, analysts predict that Opko Health will post $-0.31 earnings per share for the current fiscal year.
OPK has been the subject of a number of recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, August 13th. They now have a $10.50 price target on the stock, down previously from $11.00. Finally, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Opko Health currently has an average rating of “Buy” and a consensus price target of $12.00.
OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.